Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Fintech PR

DR CRAIG WRIGHT ISSUES SETTLEMENT OFFER TO COPA MEMBERS AND ALL PARTIES IN UPCOMING INTELLECTUAL PROPERTY LITIGATION

Published

on

dr-craig-wright-issues-settlement-offer-to-copa-members-and-all-parties-in-upcoming-intellectual-property-litigation

LONDON, Jan. 24, 2024 /PRNewswire/ — In February, I am due to face a group of individuals and corporate entities in London’s High Court, where I intend to uphold my intellectual property rights in Bitcoin as its creator.

However, the focus of my various litigations to date has never been on revealing my pseudonymous identity as Satoshi Nakamoto, but on mandating that Bitcoin remains faithful to its central principles. These are set out in the Bitcoin White Paper, today widely recognised as the authoritative foundation of all forms of Bitcoin: it describes a peer-to-peer electronic cash system, focusing on enabling small casual transactions (known as micro-payments) directly between parties, without the need for a financial intermediary.

My issuance of copyright claims against the ‘Bitcoin developers’ was a measure to protect the continuity of those principles.

To that end, today I have sent to my opponents in the COPA litigation (Claim No. IL-2021-000019), the passing-off claims (Claim No. IL-2022-000035  & Claim No. IL-2022-000036) and database-rights claims, (Claim No. IL-2022-000069) a non-negotiable offer to settle each of these cases, which is reproduced in its entirety below.

This settlement offer preserves my objective of maintaining the integrity of the Bitcoin system as it was initially developed, while limiting (for all parties) the needless expense of a lengthy High Court trial, which would take our collective focus away from supporting, adopting and advancing digital currency technologies – not just my own work, but those of potential good faith competitors (my legal opponents included).

In clear demonstration of the sincerity of my offer, I agree to waive my database rights and copyrights relating to BTC, BCH and ABC databases, and to offer an irrevocable licence in perpetuity to my opposing parties who collectively control, operate, and/or own those databases, in pursuit of encouraging the open commercialisation of technologies in a competitive and fair market, where intellectual property rights are respected and exploited.  I intend for this offer to enable them to compete fairly, in parallel with BSV.

I believe the settlement terms are broadly uncontroversial, beneficial to the industry as a whole, and intended to draw a fresh start in the history of Bitcoin to guarantee its success in whatever form it takes.

All parties now have 7 days from the date of this offer to agree this settlement, or we shall progress to trial.

Issued by:   Dr Craig Wright  All enquiries to:  [email protected]

DR WRIGHT’S OFFER TO SETTLE CLAIMS:

Claim No. IL-2021-000019 Crypto Open Patent Alliance v Dr Craig Wright

Claim No. IL-2022-000035 Dr Craig Wright & Another v. Coinbase Global, Inc & Others

Claim No. IL-2022-000036 Dr Craig Wright & Another v. Payward & Others

Claim No. IL-2022-000069 Dr Craig Wright & Another v. BTC Core & Others (Identity Issue only) (together the “Claims”)

1.  I make the below offer to each of the opposing parties in the Claims (together the “Opposition“), in order to refocus my personal priorities, which include (i) continuing to develop intellectual property for the benefit of blockchain technology and beyond, (ii) to ensure Bitcoin (in particular Bitcoin Satoshi Vision (“BSV“)) plays a key role in the development of payment infrastructure, and (iii) to spend more time with my family, amongst other things.

2.  My intention is to align with a portion of COPA’s Mission Statement which is: 

to encourage the adoption and advancement of cryptocurrency technologies“.

3.  In that respect I want to continue to be a force for good by encouraging the open commercialisation of technologies in a competitive and fair market where intellectual property rights are respected and exploited. It is therefore my intention to ensure that the relevant Bitcoin Core (“BTC“), Bitcoin Cash (“BCH“) and ABC Bitcoin (“ABC“) databases and assets can operate and compete fairly in parallel with BSV, which I hope can compete in the global community going forward.

4.  You now have the opportunity to review and accept the below offer for a total of seven days from the date of this letter, being by 4pm on 31st January 2024. It is my intention to find a sensible solution to these claims, and to allow all the parties to continue their respective projects in a competitive and commercial environment.

THE OFFER

5.  The terms of the settlement offer are made below:

6. Claims, Costs and Charitable Donations

 a.  The Claims are discontinued in their entirety and the respective claimants discontinue their claims by filing a notice of discontinuance within 24 hours of acceptance of this offer.

 b.  Costs in the Claims are borne by their respective parties (i.e. no order as to costs). I am aware COPA includes some of the largest crypto currency companies in the world (including Coinbase and Kraken), and Meta (the parent company of Facebook, Instagram and others), which I believe have significant revenue and assets. On that basis I am hopeful that the benefit of discontinuing proceedings far outweighs the costs incurred in continuing the Claims (which may endure for years).

 c.  The respective parties each make a charitable donation to Burnside, a Uniting Church in Australia (with charity number 16341259959) (the “Charity“) which supports single mothers, or alternatively another charity agreed by all parties, for the expected value of the costs of pursuing the above Claims through to the end of trial or where there are cost awards in their favour. For example, I shall make a donation of £1,000,000, which I believe is put to better use with the Charity. It is expected that Opposition evidences proof of payment publicly.

 d.  I declare and undertake to ensure that no funds or costs in these proceedings are for the financial benefit of myself and that all funds due to me shall be donated to the Charity. In that way, I do not financially profit from the Claims in any way.  

7. Bitcoin  

 a.  I, any affiliates, associates or otherwise, shall not pursue and are prevented from pursuing any database rights or copyrights (together the “Rights“) in relation to the BTC, BCH and or ABC databases, and Opposition which control operate, manage and or own those databases are granted an irrevocable licence in perpetuity to exploit, use, assign or license (subject to the below provisions) those Rights for the purposes of exploiting BTC, BCH and or ABC. It is intended that the parties continue to develop, file and respect their own patents for their respective projects and seek to rely on patents and the corresponding laws in the usual way.

 b.  Opposition including any affiliates, associates, employees or otherwise shall not pursue and are prevented from pursuing any Rights in relation to the BSV database.

 c.  By signing the below, Opposition (which includes all members of COPA) and I now confirm the following statement to be true and agree to its terms:

 “Bitcoins (and derivative systems) referred to as BSV, BTC, BCH and ABC (together “Bitcoins”), and the corresponding databases are separate and distinct. Each of these Bitcoins stem from Satoshi Nakamoto’s “Bitcoin: A Peer-to-Peer Electronic Cash System” (the “White Paper”). Satoshi Nakamoto’s original vision for Bitcoin was “small casual transactions” (see the White Paper) and scaling on-chain (see Satoshi Nakamoto’s message from 2 November 2008 “Bitcoin P2P E-Cash Paper” on the topic: https://www.metzdowd.com/pipermail/cryptography/2008-November/014815.html. I/ we recognise that BTC, BCH and ABC now have separate purposes and uses not contemplated by Satoshi Nakamoto

 I/we undertake to ensure that Bitcoins shall be used for the benefit of humankind broadly and not to launder funds, evade tax or assist in any other illicit behaviours. I/we shall use my/our best endeavours to comply with all international and national laws and regulations in which I/ we operate, including any laws relating to money laundering, and anti-terrorist financing, or similar initiatives where exploiting and developing Bitcoins and its technology, and where required and possible, actively seek to create code to ensure compliance“. 

 d.  Whether in their own capacity or by any affiliates, associates, employees or otherwise  Opposition and I shall not exploit, and be prevented from exploiting any BTC, BCH, ABC or BSV database to create, copy, fork, or otherwise, a new Bitcoin database, and Opposition and I shall use best endeavours to ensure that no third party carries out the aforesaid. It is intended that these terms are not circumnavigated by the creation of any new Bitcoin database.

 e.  Any entities shall cease claiming that they represent the original Bitcoin as envisioned by me as Satoshi Nakamoto. Additionally, they must publicly acknowledge that the intended purpose for creating Bitcoin was to create a system to provide micropayments, to allow for the chronologically ordered validation of transactions and to facilitate scalability. 

8. Media 

 a.  Opposition cease any media campaign(s) against me. 

 b.  It is intended that where this document is signed as below, that signed version is made publicly available.

9.  I believe these terms are broadly uncontroversial, beneficial to the industry as a whole, and intended to draw a fresh start in the history of Bitcoin to guarantee its success in whatever form it takes. I look forward to hearing from you.

View original content:https://www.prnewswire.co.uk/news-releases/dr-craig-wright-issues-settlement-offer-to-copa-members-and-all-parties-in-upcoming-intellectual-property-litigation-302043625.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024

Published

on

invitation-to-presentation-of-eqt-ab’s-q1-announcement-2024

STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826

The following files are available for download:

https://mb.cision.com/Main/87/3956826/2712771.pdf

Invitation to presentation of EQT AB’s Q1 Announcement 2024

https://news.cision.com/eqt/i/eqt-ab-group,c3285895

EQT AB Group

 

View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs

Published

on

kia-presents-roadmap-to-lead-global-electrification-era-through-evs,-hevs-and-pbvs
  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Published

on

biovaxys-technology-corp.-provides-bi-weekly-mcto-status-update

VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html

Continue Reading

Trending